Fuad Fares, Prof.
Founder
Claimed by owner CanCuRX
Former names:
Pancreatic Cancer Treatment
CanCuRX
About
CanCuRX is a preclinical-stage biopharmaceutical company aiming to improve survival for patients with pancreatic cancer through the development of a novel treatment based on the properties of a mushroom-derived compound that arrests pancreatic cell growth.
CanCuRX is working with the Carmel Innovations Fund of the University of Haifa.
CanCuRX has patents registered for the mushroom strain, the extract prepared from it, and the treatment process.
CanCuRX is working with the Carmel Innovations Fund of the University of Haifa.
CanCuRX has patents registered for the mushroom strain, the extract prepared from it, and the treatment process.
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
-
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
0
Investors
0
The Team
(2)
FFP
LSP
Lital Sharvit, PhD
Co-founder
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Others
Academic Techonology
Feb 2016
undefined
Pancreatic Cancer Treatment Based on Mushroom-derived Compound
Media gallery
(1)Locations
Israel
Eshkol Tower, University of Haifa, 3498838 Israel
Locations
Israel
Eshkol Tower, University of Haifa, 3498838 Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,